Oric Pharmaceuticals IncNASDAQ:ORIC
- LAST PRICE10.7350
- TODAY'S CHANGE (%)0.0050 (0.0466%)
- Bid / Lots10.7200/ 5
- Ask / Lots10.7400/ 1
- Open / Previous Close10.8000 / 10.7300
- Day Range
- 52 Week Range
- Volume158,633
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORIC |
|---|---|---|
| 09:32 ET | 3172 | 10.75 |
| 09:34 ET | 3711 | 10.57 |
| 09:36 ET | 1943 | 10.66 |
| 09:38 ET | 1400 | 10.67 |
| 09:39 ET | 3160 | 10.8 |
| 09:43 ET | 300 | 10.835 |
| 09:45 ET | 920 | 10.74 |
| 09:48 ET | 1896 | 10.79 |
| 09:50 ET | 200 | 10.78 |
| 09:52 ET | 1500 | 10.77 |
| 09:54 ET | 2062 | 10.74 |
| 09:56 ET | 622 | 10.68 |
| 10:01 ET | 2000 | 10.595 |
| 10:03 ET | 259 | 10.5949 |
| 10:06 ET | 1100 | 10.52 |
| 10:08 ET | 2027 | 10.535 |
| 10:10 ET | 4700 | 10.59 |
| 10:12 ET | 18728 | 10.79 |
| 10:14 ET | 1256 | 10.785 |
| 10:15 ET | 3542 | 10.7457 |
| 10:17 ET | 1428 | 10.7061 |
| 10:19 ET | 1143 | 10.69 |
| 10:21 ET | 1932 | 10.76 |
| 10:24 ET | 476 | 10.75 |
| 10:26 ET | 343 | 10.77 |
| 10:28 ET | 200 | 10.74 |
| 10:30 ET | 300 | 10.755 |
| 10:32 ET | 1000 | 10.73 |
| 10:33 ET | 300 | 10.7 |
| 10:35 ET | 1747 | 10.685 |
| 10:37 ET | 204 | 10.67 |
| 10:39 ET | 400 | 10.67 |
| 10:42 ET | 300 | 10.6325 |
| 10:44 ET | 300 | 10.65 |
| 10:48 ET | 200 | 10.69 |
| 10:50 ET | 100 | 10.68 |
| 10:53 ET | 800 | 10.7 |
| 10:57 ET | 209 | 10.71 |
| 11:02 ET | 628 | 10.67 |
| 11:06 ET | 450 | 10.675 |
| 11:08 ET | 825 | 10.6605 |
| 11:09 ET | 1004 | 10.7 |
| 11:11 ET | 1900 | 10.64 |
| 11:13 ET | 1400 | 10.73 |
| 11:15 ET | 518 | 10.73 |
| 11:18 ET | 200 | 10.715 |
| 11:20 ET | 100 | 10.72 |
| 11:22 ET | 150 | 10.72 |
| 11:24 ET | 1200 | 10.665 |
| 11:27 ET | 100 | 10.68 |
| 11:29 ET | 100 | 10.661 |
| 11:31 ET | 300 | 10.69 |
| 11:40 ET | 200 | 10.72 |
| 11:42 ET | 100 | 10.72 |
| 11:45 ET | 100 | 10.74 |
| 11:51 ET | 600 | 10.76 |
| 11:56 ET | 1400 | 10.74 |
| 12:00 ET | 300 | 10.74 |
| 12:02 ET | 1050 | 10.7301 |
| 12:07 ET | 120 | 10.72 |
| 12:09 ET | 300 | 10.74 |
| 12:20 ET | 100 | 10.735 |
| 12:21 ET | 167 | 10.735 |
| 12:23 ET | 100 | 10.76 |
| 12:25 ET | 238 | 10.735 |
| 12:27 ET | 100 | 10.72 |
| 12:32 ET | 100 | 10.74 |
| 12:36 ET | 100 | 10.73 |
| 12:39 ET | 307 | 10.73 |
| 12:41 ET | 100 | 10.71 |
| 12:43 ET | 600 | 10.68 |
| 12:45 ET | 700 | 10.705 |
| 12:50 ET | 400 | 10.69 |
| 12:56 ET | 1018 | 10.71 |
| 12:57 ET | 300 | 10.69 |
| 01:12 ET | 238 | 10.67 |
| 01:14 ET | 427 | 10.69 |
| 01:15 ET | 400 | 10.695 |
| 01:17 ET | 200 | 10.69 |
| 01:21 ET | 100 | 10.72 |
| 01:24 ET | 10391 | 10.75 |
| 01:26 ET | 908 | 10.755 |
| 01:30 ET | 100 | 10.75 |
| 01:32 ET | 146 | 10.755 |
| 01:33 ET | 100 | 10.74 |
| 01:35 ET | 300 | 10.745 |
| 01:37 ET | 1398 | 10.71 |
| 01:39 ET | 400 | 10.7 |
| 01:42 ET | 100 | 10.7 |
| 01:44 ET | 100 | 10.71 |
| 01:46 ET | 100 | 10.7 |
| 01:48 ET | 500 | 10.73 |
| 01:50 ET | 977 | 10.78 |
| 01:53 ET | 300 | 10.765 |
| 01:55 ET | 300 | 10.77 |
| 01:57 ET | 100 | 10.75 |
| 02:00 ET | 200 | 10.751 |
| 02:02 ET | 339 | 10.765 |
| 02:04 ET | 100 | 10.77 |
| 02:08 ET | 300 | 10.8 |
| 02:13 ET | 320 | 10.815 |
| 02:15 ET | 100 | 10.815 |
| 02:18 ET | 2565 | 10.7808 |
| 02:20 ET | 402 | 10.765 |
| 02:22 ET | 800 | 10.785 |
| 02:24 ET | 300 | 10.76 |
| 02:26 ET | 200 | 10.75 |
| 02:27 ET | 100 | 10.74 |
| 02:29 ET | 600 | 10.76 |
| 02:31 ET | 300 | 10.74 |
| 02:33 ET | 200 | 10.74 |
| 02:38 ET | 300 | 10.77 |
| 02:40 ET | 100 | 10.77 |
| 02:49 ET | 200 | 10.74 |
| 03:02 ET | 200 | 10.71 |
| 03:03 ET | 539 | 10.735 |
Sep 18, 2024
DJ Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 1:42PM ET on Wednesday Sep 18, 2024 by Dow Jones
1:42PM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 10, 2024
DJ Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush, from 9:08AM ET on Tuesday Sep 10, 2024 by Dow Jones
9:08AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 6, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Sep 06, 2024 by Dow Jones
4:30PM ET on Friday Sep 06, 2024 by Dow JonesDJ Oric Pharmaceuticals Initiated at Buy by Stifel, from 11:39AM ET on Friday Sep 06, 2024 by Dow Jones
11:39AM ET on Friday Sep 06, 2024 by Dow Jones
Aug 26, 2024
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences, from 4:05PM ET on Monday Aug 26, 2024 by Dow Jones
4:05PM ET on Monday Aug 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oric Pharmaceuticals Inc | 756.9M | -6.1x | --- |
Savara Inc | 758.8M | -10.1x | --- |
Arrivent Biopharma Inc | 760.4M | -9.7x | --- |
Replimune Group Inc | 748.8M | -3.4x | --- |
Olema Pharmaceuticals Inc | 743.3M | -6.3x | --- |
Rapport Therapeutics Inc | 736.6M | 0.0x | --- |
Company Information
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Contact Information
- Headquarters
- 240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-388-5600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Heyman
- President, Chief Executive Officer, Director
- Jacob Chacko
- Chief Financial Officer
- Dominic Piscitelli
- Chief Medical Officer
- Pratik Multani
- Independent Director
- Mardi Dier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $756.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
